Immuneel - About the company
Immuneel is a series B company based in Bengaluru (India), founded in 2018 by Siddhartha Mukherjee and Kush Parmar. It operates as a Developer of T-cell therapies for the treatment of cancer. Immuneel has raised $49.8M in funding from investors like Khosla Ventures, True North Venture Partners and Syngene, with a current valuation of $*****. The company has 3472 active competitors, including 1156 funded and 809 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells. It has developed CAR-T cell therapy extracted from patient's blood cells to target cancerous cells. The product pipeline includes IMN-003A, IMN-001, and IMN-002 for leukemias and lymphomas.
- Website
- immuneel.com
- Email ID
- *****@immuneel.com
- Registered Address
- 29/P2, 8TH FLOOR, NARAYANA HEALTH CITY HOSUR ROAD, BOMMASANDRA INDUSTRIAL AREA, Bangalore, BENGALURU, Karnataka, India, 560099
Key Metrics
Founded Year
2018
Location
Bengaluru, India
Stage
Series B
Total Funding
$49.8M in 5 rounds
Latest Funding Round
Post Money Valuation
$***** as on Jun 24, 2024
Investors
Ranked
8th among 3472 active competitors
Annual Revenue
0 - ₹10 Cr as on Mar 31, 2025
Employee Count
70 as on Aug 31, 2025
Similar Companies
Legal entities associated with Immuneel
Immuneel is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
IMMUNEEL THERAPEUTICS PRIVATE LIMITED CIN: U24230KA2018PTC119691 , India, Active | Dec 20, 2018 | 0 - ₹10 Cr (As on Mar 31, 2025) | 70 (As on Aug 01, 2025) |
Sign up to download Immuneel's company profile
Immuneel's funding and investors
Immuneel has raised a total funding of $49.8M over 5 rounds. Its first funding round was on Nov 20, 2019. Its latest funding round was a Series B round on Jun 08, 2026 for $*****. 5 investors participated in its latest round. Immuneel has 19 institutional investors and 6 angel investors.
Here is the list of recent funding rounds of Immuneel:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 08, 2026 | 7112626 | Series B | 5104512 | 1127314 | 9621721 | 7974624 |
Jun 24, 2024 | 4642689 | Series A | 7631680 | 9877581 | 6772574 | |
Apr 11, 2022 | 8046471 | Series A | 6102175 | 1242377 |
Access funding benchmarks and valuations. Sign up today!View details of Immuneel's funding rounds and investors
Immuneel's founders and board of directors
Founder? Claim ProfileThe founders of Immuneel are Siddhartha Mukherjee and Kush Parmar.
Here are the details of Immuneel's key team members:
- Siddhartha Mukherjee: Co-Founder of Immuneel and founder of 2 other companies, CuraPatient and Vor Biopharma. They serve on the board of 1 company.Contact Info: 2 email addresses
- Kush Parmar: Co-Founder of Immuneel.
Immuneel's Board of Directors
Immuneel's board has 4 active members. Kiran Mazumdar Shaw and Siddhartha Mukherjee are part of team and Ranjan Ramdas Pai and Saif Khalfan Mohamed Al Hasani are independent board members.Here is the list of Immuneel's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 7y 9m | |
Team | - | Current | 4y 5m | |
Independent board member | - | Current | 7y 9m | |
{xh{opt | Independent board member | - | Current | 6y 4m |
View details of Immuneel's Founder profiles and Board Members
Immuneel's employee count trend
Immuneel has 70 employees as of Aug 25. The total employee count is 4.0% more than what it was in Aug 24. Here is Immuneel's employee count trend over the years:
Uncover Immuneel's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immuneel's Competitors and alternates
Top competitors of Immuneel include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Immuneel, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immuneel's competitors? Click here to see the top ones
Immuneel's Latest cap tables and shareholding
Founders own 15.99%, Funds own 26.90%, Enterprises (largest shareholder) own 36.04% and Angels own 12.71%. The net worth of Immuneel's founders is INR 94.1Cr as of Jun 24, 2024.
Shareholders Name | Post Round Holding % | Net worth | Cumulative Investment | Realised Returns | Unrealised Returns | Return Multiple |
|---|---|---|---|---|---|---|
Founder | 15.99% | 94.1Cr | 2254613 | 1383105 | 6285850 | 6535828 |
611523 | 418480 | 817336 | 647302 | 259647 | 908844 | |
291147 | 619225 | 422728 | 141225 | 288359 | 165683 | |
Fund | 26.90% | 158Cr | 2998754 | 5911828 | 8699754 | 8469751 |
398811 | 304150 | 324729 | 764780 | 885685 | 299289 | |
92588 | 80247 | 48324 | 14906 | 86644 | 22651 | |
90 | 67 | 48 | 85 | 90 | 31 | |
Enterprise | 36.04% | 212Cr | 9237607 | 1045632 | 8611010 | 9718535 |
Angel | 12.71% | 74.8Cr | 5962239 | 6152015 | 7513085 | 2927043 |
94462 | 53546 | 10577 | 42189 | 64514 | 77594 | |
ESOP Pool | 8.34% | 49.1Cr | 7975356 | 8485385 | 5216674 | 2525637 |
Total | 99.98% | 588Cr | 1241990 | 8492333 | 1272899 | 5960890 |
To unlock detailed Cap Table of Immuneel Sign up today!Notes: The column Net Worth represents the net worth of investments made by that entity, as per the latest cap table.
DisclaimerView more details of Immuneel's Shareholding
Immuneel's Investments and acquisitions
Immuneel has made no investments or acquisitions yet.
Reports related to Immuneel
Here is the latest report on Immuneel's sector:
News related to Immuneel
Filter this listMedia has covered Immuneel for a total of 6 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
Sun Pharma inches closer to biggest-ever buyout as Organon shareholders approve mergerMoneycontrol•Jul 24, 2026•Sun Pharma, Organon, Immuneel
•
Immuneel Therapeutics partners with Arogya Finance for zero-cost EMI cancer treatment programIndiatimes•Jul 06, 2026•Immuneel, Arogya Finance
•
Immuneel Therapeutics Secures Over Rs 100 Cr in Series B Funding RoundEntrackr•Jun 08, 2026•Singularity AMC, Immuneel, Rainmatter, Zerodha and 4 others
•
Immuneel Therapeutics partners with Impact Guru and CarePal Money to improve access to CAR T-Cell therapyIndiaMedToday•Jan 08, 2026•Immuneel, ImpactGuru
•
ScaleReady awards $150,000 grant to Immuneel Therapeutics for CAR-T cell manufacturing in IndiaBioSpectrum India•Jun 11, 2025•ScaleReady, Immuneel
•
Immuneel Therapeutics unveils India’s first global CAR T-cell therapy for Non-Hodgkin’s LymphomaBioSpectrum India•Jan 20, 2025•Immuneel
•
•
•
Taiba makes $12 M investment in Immuneel Therapeutics to advance CAR T-cell researchBioSpectrum Asia•Jul 30, 2024•Taiba, Immuneel
•
taiba Make Strategic Investment in Immuneel Therapeutics to advance CAR T-cell Research and Make Therapies More Affordable.Business Wire•Jul 30, 2024•Taiba, Immuneel
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immuneel
Explore our recently published companies
- Una Home Care - Beverly Hills based, 2026 founded, Unfunded company
- Boooply - 2026 founded, Unfunded company
- Uaity - 2026 founded, Unfunded company
